MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Maturities of marketablesecurities$40,000K Proceeds from issuancesof common stock...$2,102K Net cash provided by(used in) investing...$17,854K Net cash provided byfinancing activities$2,102K Canceled cashflow$22,146K Net cash increase(decrease) for the period-$11,120K Canceled cashflow$19,956K Stock-based compensation$10,232K Accounts payable,accrued expenses and...$5,318K Depreciation$138K Right-of-use assets and leaseliabilities, net$17K Purchases of marketablesecurities$22,080K Purchases of property andequipment$66K Net cash used inoperating activities-$31,076K Canceled cashflow$15,705K Net loss-$45,558K Prepaid expenses andother assets$1,018K Accretion on marketablesecurities, net-$205K
Cash Flow

Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. (TYRA)

source: myfinsight.com